MyMD PHARMACEUTICALS

FACT SHEET

NASDAQ: MYMD
AUTUMN 2021

NOVEL IMMUNOTHERAPIES TARGETING AGING AND RELATED DISEASES

MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) a clinical stage pharmaceutical company committed to extending healthy lifespan, is focused on developing two novel therapeutic platforms that treat the causes of disease rather than only addressing the symptoms. MYMD-1 is a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-α, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. MYMD-1 is being developed to delay aging, increase longevity, and treat autoimmune diseases and COVID-19- associated depression. The Company's second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction and epilepsy. Supera-CBD is a novel synthetic derivative of cannabidiol (CBD) and is being developed to address and improve upon the rapidly growing CBD market, which includes both FDA approved drugs and CBD products not currently regulated as drugs. For more information, visit www.mymd.com.

KEY INVESTMENT CONSIDERATIONS

- **Advancing lead drug candidate MYMD-1 in the clinic with two simultaneous Phase 2 trials beginning in Q4 2021**
  - Delaying aging and prolonging lifespan
  - COVID-19-associated depression and cytokine elevation
- **Recent research has demonstrated multifunctionality of second drug candidate Supera-CBD with superior potency over CBD by a factor of 8,000 times**
  - Leveraging pre-existing market acceptance and FDA's declared receptiveness to moving forward in this space to address a widespread unmet need for pharmaceutical cannabinoids
- **Massive addressable markets with no competing FDA-approved drugs for treating aging disorders and extending healthy lifespan**
  - Market expected to be at least $600 billion by 2025 according to a major investment bank[1]
  - TNF-α blockers are the most prescribed drugs by revenue, a global market of about $40 billion per year[2]
  - A slowdown in aging that would increase life expectancy by one year is worth $38 trillion and by 10 years is worth $367 trillion[3]
- **Diversified, high-value IP portfolio**
  - 13 granted patents for MYMD-1 and 1 for Supera-CBD
  - 34 patent applications pending worldwide
- **Subsidiary Oravax Medical preparing to commence clinical trials for oral COVID-19 vaccine**
  - Alongside majority partner Oramed Pharmaceuticals Inc. (Nasdaq: ORMP), MyMD owns 13% of Oravax's outstanding shares of capital stock and a 2.5% royalty on all future net sales
  - Partners evaluating options with respect to interests in Oravax including a potential distribution of Oravax shares to shareholders
- **Strong financial position**
  - Ample cash resources to fund drug research and development through early 2024

PIPELINE



MARKET SNAPSHOT

Share Price	$7.39 (10/11/21)
52-Wk. Range	$3.30-$10.48
Avg. Vol.	238K
Shares O/S	37.3M
Market Cap	$276.1M

Price and volume quotes from Yahoo! Finance

MyMD Pharmaceuticals

855 N Wolfe St, Ste 623
Baltimore, Maryland 21205
www.mymd.com

Investor Relations Contact

Robert Schatz
rschatz@mymd.com
646-421-9523

Sources: (1) https://www.cnbc.com/2019/05/08/techs-next-big-disruption-could-be-delaying-death.html (2) October 9, 2019, Tumor Necrosis Factor (TNF) Inhibitor Drugs Market, Acumen Research and Consulting (3) Nature Aging | VOL 1 | July 2021 | p. 616–623

RECENT DEVELOPMENTS

- *Announced new data demonstrating 8,000 times higher potency of novel synthetic Supera-CBD over plant-derived CBD*
- *Announced fourth quarter 2021 initiation of Phase 2 clinical trial of MYMD-1 for extending healthy lifespan*
- *Announced issuance of U.S. patent for use of MYMD-1 for treating fibrosis and asthma*
- *Announced issuance of U.S. patent for synthetic cannabinoid compounds for treating neuroinflammatory and neurodegenerative diseases*
- *MyMD's subsidiary Oravax Medical preparing to commence clinical trials for oral COVID-19 vaccine*
- *MYMD-1 shown to suppress a major cause of death in COVID-19 in human cell study*
- *MYMD-1 shows commonality in comparative study with FDA-approved anti- inflammatory and anti-autoimmune drugs used for arthritis, colitis and dermatitis*

MYMD-1

MYMD-1 is a clinical-stage immuno regulator that performs as a selective inhibitor of tumor necrosis factor-alpha (TNF-α), a driver of chronic inflammation. MYMD-1's primary purpose is to slow the aging process and extend healthy lifespan, and it is also showing promise as a potential treatment for post- COVID-19 complications and as an anti-fibrotic and anti-prolific therapeutic.

- MYMD-1's ease of oral dosing is a groundbreaking differentiator compared to currently available TNF-α blockers, all of which require delivery by injection or infusion. No approved TNF inhibitor has ever been dosed orally.
- Unlike other therapies, MYMD-1 is designed to selectively block TNF-α when it becomes overactivated in autoimmune diseases and cytokine storms, but not to block it from doing its normal job of being a first responder to any routine type of moderate infection.
- The drug is not immunosuppressive and has not been shown to cause serious side effects common with traditional therapies that treat inflammation.

SUPERA-CBD

Supera-CBD is a pre-clinical patented synthetic CBD derivative that is being developed as a pharmaceutical drug to address anxiety, pain, and neurodegeneration. At 8,000 times the potency of regular CBD, MyMD believes that Supera-CBD shows strong potential as a therapeutic for high-threat diseases and conditions like Alzheimer's, psychosis, neuropathic pain, addiction, and anxiety.

- Supera-CBD is estimated by MyMD to be between 40 to 500 times the potency of the first discovered and best-characterized endocannabinoids anandamide and 2-arachidonoyl glycerol, which are produced naturally inside the body.
- Supera-CBD is non-toxic and approximately 7-8X more effective than plant-derived CBD in reducing MAO-A and MAO-B, which play a role in substance addiction.
- Supera-CBD is currently on a path toward human clinical trials as a therapy for epilepsy, followed by chronic pain.

LEADERSHIP

Chris Chapman, M.D., President, Chief Medical Officer and Director: Prior to joining MyMD and since 1999, Dr. Chapman has also served as the CEO of Chapman Pharmaceutical Consulting, Inc., a consulting organization that provides support to pharmaceutical and biotech companies in North America, Europe, Japan, India and Africa on issues such as product safety, pharmacovigilance, medical devices, clinical trials and regulatory issues.

Adam Kaplin, M.D., PH.D., Chief Scientific Officer: Prior to joining MyMD, Dr. Kaplin has served in a number of positions at John Hopkins University, including Principal Neuro-Psychiatric Consultant to the Johns Hopkins Multiple Sclerosis Center of Excellence, Director of the Johns Hopkins Ketamine Clinic and the Departments of Psychiatry & Neurology at Johns Hopkins University School of Medicine, positions he has held at various times from 2002 to present.

Paul Rivard, ESQ., VP of Operations & General Counsel: Prior to joining MYMD, Mr. Rivard was a principal shareholder of Banner Witcoff, a national law firm specializing in intellectual property law, from 2003-2020, and in that capacity also served as Chair of the firm's Prosecution Policies and Procedures Committee, developing and refining internal procedures, workflow, and docketing practices to improve efficiencies and mitigate risk.

Josh Silverman, Chairman: Currently serves as the managing member of Parkfield Funding LLC. Mr. Silverman was the co-founder, and a principal and managing partner of Iroquois Capital Management, LLC ("Iroquois"), an investment advisory firm.